Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease.
Coronary artery disease
Diabetes mellitus
Metabolomic profiling
Metabolomics biomarkers
SYNTAX score
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
07 05 2022
07 05 2022
Historique:
received:
05
03
2022
accepted:
06
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM or CAD. However, studies assessing the predictive capacity of novel metabolomics biomarkers in coexistent CAD and DM are scarce. This post-hoc analysis of the CorLipid trial (NCT04580173) included 316 patients with CAD and comorbid DM who underwent emergency or elective coronary angiography due to acute or chronic coronary syndrome. Cox regression analyses were performed to identify metabolomic predictors of the primary outcome, which was defined as the composite of major adverse cardiovascular or cerebrovascular events (MACCE: cardiovascular death, myocardial infarction, stroke, major bleeding), repeat unplanned revascularizations and cardiovascular hospitalizations. Linear regression analyses were also performed to detect significant predictors of CAD complexity, as assessed by the SYNTAX score. After a median 2-year follow up period (IQR = 0.7 years), the primary outcome occurred in 69 (21.8%) of patients. Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years and presence of acute coronary syndrome were independent predictors of the primary outcome in diabetic patients with CAD (aHR = 1.89 [1.09, 3.29]; 1.02 [1.01, 1.04]; 1.28 [1.01, 1.41]; 1.04 [1.01, 1.05]; and 1.12 [1.05-1.21], respectively). Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65 and peripheral artery disease were independent predictors of higher CAD complexity (adjusted β = 7.36 [5.74, 20.47]; 3.02 [0.09 to 6.06]; 3.02 [0.09, 6.06], respectively), while higher levels of apoA1 were independent predictors of lower complexity (adjusted β= - 0.65 [- 1.31, - 0.02]). In patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice. These associations should be interpreted taking into account the observational nature of this study, and thus, larger trials are needed to confirm its results and validate them in different and larger diabetic populations.
Sections du résumé
BACKGROUND
Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM or CAD. However, studies assessing the predictive capacity of novel metabolomics biomarkers in coexistent CAD and DM are scarce.
METHODS
This post-hoc analysis of the CorLipid trial (NCT04580173) included 316 patients with CAD and comorbid DM who underwent emergency or elective coronary angiography due to acute or chronic coronary syndrome. Cox regression analyses were performed to identify metabolomic predictors of the primary outcome, which was defined as the composite of major adverse cardiovascular or cerebrovascular events (MACCE: cardiovascular death, myocardial infarction, stroke, major bleeding), repeat unplanned revascularizations and cardiovascular hospitalizations. Linear regression analyses were also performed to detect significant predictors of CAD complexity, as assessed by the SYNTAX score.
RESULTS
After a median 2-year follow up period (IQR = 0.7 years), the primary outcome occurred in 69 (21.8%) of patients. Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years and presence of acute coronary syndrome were independent predictors of the primary outcome in diabetic patients with CAD (aHR = 1.89 [1.09, 3.29]; 1.02 [1.01, 1.04]; 1.28 [1.01, 1.41]; 1.04 [1.01, 1.05]; and 1.12 [1.05-1.21], respectively). Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65 and peripheral artery disease were independent predictors of higher CAD complexity (adjusted β = 7.36 [5.74, 20.47]; 3.02 [0.09 to 6.06]; 3.02 [0.09, 6.06], respectively), while higher levels of apoA1 were independent predictors of lower complexity (adjusted β= - 0.65 [- 1.31, - 0.02]).
CONCLUSIONS
In patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice. These associations should be interpreted taking into account the observational nature of this study, and thus, larger trials are needed to confirm its results and validate them in different and larger diabetic populations.
Identifiants
pubmed: 35525960
doi: 10.1186/s12933-022-01494-9
pii: 10.1186/s12933-022-01494-9
pmc: PMC9077877
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT04580173']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
70Informations de copyright
© 2022. The Author(s).
Références
Atherosclerosis. 2019 Mar;282:169-175
pubmed: 30463677
Circulation. 2007 Jan 30;115(4):450-8
pubmed: 17190864
Am Heart J. 2012 May;163(5):844-850.e1
pubmed: 22607863
Circ Cardiovasc Genet. 2010 Apr;3(2):207-14
pubmed: 20173117
Cardiol Clin. 2014 Aug;32(3):439-55
pubmed: 25091969
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2826-2837
pubmed: 30522646
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1558-1569
pubmed: 33596665
Int Heart J. 2017 Aug 3;58(4):475-480
pubmed: 28717115
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):830-5
pubmed: 10712410
J Pers Med. 2021 Jan 31;11(2):
pubmed: 33572568
Diabetes Metab Syndr Obes. 2017 Aug 14;10:345-361
pubmed: 28860833
Nat Rev Cardiol. 2021 Oct;18(10):701-711
pubmed: 33772258
Physiol Rep. 2016 Dec;4(23):
pubmed: 27956466
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Cardiovasc Diabetol. 2021 Sep 15;20(1):188
pubmed: 34526013
Circulation. 2008 Mar 25;117(12):1563-73
pubmed: 18332268
Cardiovasc Diabetol. 2018 May 1;17(1):56
pubmed: 29712560
Cardiovasc Diabetol. 2011 Nov 10;10:98
pubmed: 22074110
Front Endocrinol (Lausanne). 2020 Sep 29;11:570628
pubmed: 33133018
Diabetes Care. 2012 Dec;35(12):2540-7
pubmed: 22933430
BMC Cardiovasc Disord. 2021 Feb 8;21(1):79
pubmed: 33557756
Circ Cardiovasc Genet. 2017 Apr;10(2):
pubmed: 28360086
BMC Cardiovasc Disord. 2021 Jun 8;21(1):284
pubmed: 34103005
Biomolecules. 2022 Feb 23;12(3):
pubmed: 35327546
N Engl J Med. 2019 Jun 27;380(26):2529-2540
pubmed: 31242362
Diabetes Metab. 2006 Dec;32(6):604-10
pubmed: 17296514
Curr Pharm Biotechnol. 2006 Aug;7(4):235-40
pubmed: 16918400
JAMA. 2002 May 15;287(19):2570-81
pubmed: 12020339
Cardiovasc Diabetol. 2021 Feb 11;20(1):40
pubmed: 33573666
Front Endocrinol (Lausanne). 2020 May 05;11:212
pubmed: 32431666
J Gerontol A Biol Sci Med Sci. 2006 Dec;61(12):1262-6
pubmed: 17234819
Circ Res. 2018 Apr 27;122(9):1238-1258
pubmed: 29700070
J Am Heart Assoc. 2019 Mar 5;8(5):e011818
pubmed: 30819029
Heart Fail Rev. 2014 Jan;19(1):35-48
pubmed: 23443849
Metallomics. 2017 Jun 21;9(6):734-743
pubmed: 28518204
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870
pubmed: 28007146
J Diabetes Sci Technol. 2015 Mar;9(2):169-76
pubmed: 25591856
Lipids Health Dis. 2020 Jun 25;19(1):151
pubmed: 32586390
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
J Am Heart Assoc. 2017 Feb 3;6(2):
pubmed: 28159823
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Diabetes Care. 2020 Jun;43(6):1200-1208
pubmed: 32161049
Circulation. 2019 Oct;140(14):1170-1184
pubmed: 31567014
Anal Bioanal Chem. 2022 Apr;414(9):3095-3108
pubmed: 35178602